VACCINE DEVELOPMENT


Looking back and looking ahead


Michael Breen, PhD, director of infectious diseases and ophthalmology at GlobalData Healthcare, discusses how controlling the coronavirus outbreak affected vaccine programme implementation and the running of clinical trials.


impossible to predict the scope of the remarkable and seemingly indelible effects that the resulting pandemic would have on the world. While measures such as masks and social distancing were implemented and have proven effective at curbing the spread, these interventions are untenable due to the social and economic strains they place on society.


W 20 | H1 Virtual Events: Review and Summary Handbook


hen the COVID-19 outbreak was first reported in Wuhan, China on 31 December 2019, it was


Moreover, these measures merely suppress the spread of the virus; upon their removal, the virus has shown it can rapidly return. In order to truly stem the tide of the pandemic, pharmaceutical interventions are obligate tools for both reducing the spread of the virus and for treating the infected. The dynamics of social and behavioural measures to control the outbreak have had an unintended impact on the pharmaceutical industry’s ability to run trials for emerging agents. These effects merit reflection and consideration,


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58